🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. Famciclovir 500 mg Tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  2. Fasinumab

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  3. Fasinumab AI

    Regeneron UK Limited

    Osteoarthritis, Knee

    phase 1 small molecule completed

    1 trial

  4. Faster Aspart

    Novo Nordisk A/S

    Diabetes Mellitus, Type 1

    phase 1 small molecule completed

    1 trial

  5. Fexofenadine 180 mg tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  6. Fexofenadine Hydrochloride without sodium lauryl sulfate

    BRIGHT MINDS BIOSCIENCES INC.

    The Impact of Excipients on Drug Absorption

    phase 1 small molecule completed

    1 trial

  7. Filgotinib

    Lakefront Biotherapeutics NV

    Bioavailability

    phase 1 small molecule completed

    1 trial

  8. Fimasartan/Atorvastatin Combination Tablet

    Yung NA

    Hypertension

    phase 1 small molecule completed

    1 trial

  9. Finasteride 5 mg tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  10. Finlepsin 200 retard, 200 mg, tabletki o przedłużonym uwalnianiu, Orungal, 100 mg, kapsułki, Gemfibrozilo STADA 600 mg comprimidos recubiertos con película EFG, Neurotop retard 300, 300 mg, tabletki o przedłużonym uwalnianiu

    Minoryx Therapeutics S.L.

    Adrenoleukodystrophy

    phase 1 small molecule active

    1 trial

  11. First-In-Human study evaluating the Safety of administration of ABD-3001 to Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes

    Advanced Accelerator Applications

    Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes, Ineligible for Intensiveor New Generation Targeted Therapy

    phase 1 other active

    1 trial

  12. First-in-Human Study of RO7812653

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitive Impairment due to AD, or probable AD dementia)

    phase 1 other active

    1 trial

  13. First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

    Genmab A/S

    Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

    phase 1 other active

    1 trial

  14. First-in-human Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of the Adjuvanted Universal Influenza Vaccine “fH1/DSP-0546LP” in Healthy Adults

    Lacuna Pharma Pty Ltd

    Influenza

    phase 1 other active

    1 trial

  15. First-line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancer (ES SCLC) (DeLLphi-303)

    Amgen

    Extensive Stage Small cell lung cancer (ES-SCLC)

    phase 1 other active

    1 trial

  16. Fludarabine

    Zafatek

    Hematologic Malignancies

    phase 1 small molecule completed

    1 trial

  17. Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)

    RIGEL PHARMACEUTICALS INC

    Pancreatic Ductal Adenocarcinoma (PDAC)

    phase 1 other active

    1 trial

  18. Freethiadine tablets(part I)

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Hepatitis B, Chronic

    phase 1 small molecule completed

    1 trial

  19. GEN1042

    Genmab A/S

    Malignant Solid Tumor

    phase 1 mab active

    1 trial

  20. GLPG0634, Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets

    Alfasigma S.p.A.

    juvenile idiopathic arthritis

    phase 1 small molecule active

    1 trial

  21. GLPG1205 film-coated tablets

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  22. GLPG1690 film-coated tablets

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  23. GLPG1972 film-coated tablets

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  24. GLPG3970 film-coated tablet

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources